2004
DOI: 10.1111/j.0013-9580.2004.56902.x
|View full text |Cite
|
Sign up to set email alerts
|

Antimyoclonic Effect of Levetiracetam in 13 Patients with Unverricht–Lundborg Disease: Clinical Observations

Abstract: Summary:Purpose: Disabling myoclonus is the main symptom in long-standing Unverricht-Lundborg disease (ULD), and levetiracetam (LEV) appears to be an effective anticonvulsant with promising short-term antimyoclonic properties.Methods: LEV was prescribed to 13 patients with ULD. We retrospectively analyzed the efficacy of LEV on seizure frequency and on myoclonus, by using a simplified myoclonus rating score, and compared the patients' status before LEV and at the last follow-up. They were two women and 11 men,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
50
0
1

Year Published

2005
2005
2015
2015

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 98 publications
(52 citation statements)
references
References 12 publications
1
50
0
1
Order By: Relevance
“…The diagnosis of EPM1 was hypothesised on the basis of its typical electroclinical presentation and confirmed by the finding of a dodecamer expansion of the cstb gene (Virtaneva et al 1997). The enrolled patients presented with mildly to moderately severe myoclonus (a score of two or three on a simplified rating scale, Magaudda et al 2004) and were receiving similar anti-epileptic treatment: valproate (10), levetiracetam (3), topiramate (2), benzodiazepine (1), bromazepam (1), clonazepam (1), lamotrigine (1), phenobarbital (1), and piracetam (1).…”
Section: Subjectsmentioning
confidence: 96%
“…The diagnosis of EPM1 was hypothesised on the basis of its typical electroclinical presentation and confirmed by the finding of a dodecamer expansion of the cstb gene (Virtaneva et al 1997). The enrolled patients presented with mildly to moderately severe myoclonus (a score of two or three on a simplified rating scale, Magaudda et al 2004) and were receiving similar anti-epileptic treatment: valproate (10), levetiracetam (3), topiramate (2), benzodiazepine (1), bromazepam (1), clonazepam (1), lamotrigine (1), phenobarbital (1), and piracetam (1).…”
Section: Subjectsmentioning
confidence: 96%
“…The diagnosis of ULD was hypothesized on the basis of the typical electroclinical presentation and confirmed by the finding of dodecamer expansion at the cstb gene (Virtaneva et al 1997). Myoclonus severity was scored using a simplified rating scale ranging from 0 (no myoclonus) to 5 (severe myoclonus) (Magaudda et al 2004). A neuroradiologist visually assessed all structural MRI images in order to exclude macroscopic anatomical abnormalities.…”
Section: Participantsmentioning
confidence: 99%
“…Routine hematologic/biochemical investigations and neuropsychological testing were performed in all cases. Severity of myoclonus was scored according to a simplified myoclonus rating scale, as described (5). Electrophysiologic study included EEG, somatosensory evoked potentials (SEPs), and Long-Loop Reflex I (LLRI).…”
mentioning
confidence: 99%